• Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
Biotech Leaders Get It
  • Traverse
    • Timmerman Traverse for LSC 2025
    • Past Climbs (2018-2025)
  • Speaking
  • About
    • Community
    • Frontpoints
    • Podcast
    • Events
    • Advisors
    • Team
      • David Shaywitz
      • Alex Harding
      • Pedro Rafael Rosado
      • Steve White
    • Hood Biography
    • In the News
    • Testimonials
  • Contact
  • Subscribe
    • Individual Subscriptions
    • Group Subscriptions
16
May
2017

Biotech People Care, But How Can the Industry Make a Difference?

/
Luke Timmerman
/
0
/
All, The Edge
16 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
12
May
2017

Palpitations in PD-1/PD-L1 Land, a Mystery ALS Drug Approval, And a CAR-T Scare

/
Luke Timmerman
/
0
/
All
12 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
8
May
2017

Seattle Biotech: See You at the TR 2nd Anniversary Party Tuesday at Adaptive

/
Luke Timmerman
/
0
/
All
08 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
May
2017

House Passes Trumpcare, Alzheimer’s Drug Shenanigans, & An IPO Flurry

/
Luke Timmerman
/
0
/
All
05 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
1
May
2017

Who’s Doing What in Long-Read and Linked-Read DNA Sequencing

/
Luke Timmerman
/
0
/
All, The Edge
01 May 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
28
Apr
2017

Biotech Execs Going to White House, NASH Buzz, & Zuckerberg Bankrolls Preprint Movement

/
Luke Timmerman
/
0
/
All
28 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
24
Apr
2017

David Baltimore on What it Takes to Create the Future

/
Luke Timmerman
/
0
/
All, People
24 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
22
Apr
2017

Steve Holtzman on Why Biotech Should Stand Up for Science

/
Steve Holtzman
/
1
/
All, People, Politics
22 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
21
Apr
2017

Verily, Verily Everywhere, Tesaro’s Cheaper PARP (Not Really), and a Juno Exec Shakeup

/
Luke Timmerman
/
0
/
All
21 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
20
Apr
2017

Lessons from PCSK9, and How We Know Where to Go in Drug Discovery

/
Kyle Serikawa
/
0
/
All, Drugs, Science
20 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
19
Apr
2017

Photos from the TR Anniversary Party and Boston Marathon

/
Luke Timmerman
/
0
/
All
19 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
17
Apr
2017

It’s Time for a Human Knockout Project to Advance Drug Discovery

/
Robert Plenge
/
3
/
All, Drugs, Science
17 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
14
Apr
2017

SEC Busts Paid Stock Pumpers, Neurocrine Scores FDA OK, BMS Unloads Two Assets

/
Luke Timmerman
/
0
/
All
14 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
11
Apr
2017

Boston Biotech: See You At The TR Anniversary Party Thursday Afternoon

/
Luke Timmerman
/
0
/
All
11 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
7
Apr
2017

Gottlieb Nails Senate Hearing, 23andMe Back in FDA’s Good Grace, and AACR Reflections

/
Luke Timmerman
/
0
/
All
07 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
6
Apr
2017

AACR Reflections: Genomics Adapts to I-O World, Scientists Stand Up, and Re-Thinking How to Fight Early-Stage Cancer

/
Sam Blackman
/
1
/
All, Cancer, Drugs
06 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
5
Apr
2017

Allen’s $100M Cell Biology Resource a Cool Idea With a Long Way to Go, Scientists Say

/
Luke Timmerman
/
0
/
All, Science
05 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
3
Apr
2017

Six Clues That Show When an Academic Institution Is Serious About Entrepreneurship

/
Luke Timmerman
/
0
/
All, Politics, The Edge
03 Apr 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
31
Mar
2017

FDA Commish Scrutiny, and a String of Big Approvals for Regeneron, Tesaro & Genentech

/
Luke Timmerman
/
0
/
All
31 Mar 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
30
Mar
2017

Third Rock’s Tango Gets $55M for CRISPR-Enabled Synthetic Lethal Cancer Combos

/
Luke Timmerman
/
3
/
All, Cancer, Drugs
30 Mar 2017

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $169 per year, you reward quality independent biotech reporting, and encourage more.

 
Subscribe Now
 
Sign in to your account.
‹ Previous 1 … 63 64 65 66 67 … 80 Next ›

Get In-depth Biotech Coverage with Timmerman Report.

Individual Subscription

Group Subscription

Or: Sign in to your account

Your account

Sign in

What Readers Are Saying

testimonial

View More Testimonials ➛

© Copyright 2025, TimmermanReport.com
Privacy Policy | Terms of Use
Custom WordPress site by: Perception Builder